Audiology: Navigating Progressive Hearing Loss
At a Glance
Mitochondrial disease linked to the m.3243A>G variant can cause progressive hearing loss in both ears and may reduce speech clarity as well as volume. Regular audiology testing, well-fitted hearing aids, communication supports, and carefully assessed cochlear implants can help maintain communication.
Hearing loss is one of the most common features of the m.3243A>G variant, occurring in more than half of all people with this genetic change [1]. Because the inner ear and the auditory nerve require high levels of energy to function, they are particularly vulnerable to the “energy crisis” caused by mitochondrial dysfunction [2].
EMERGENCY ALERT: Sudden Hearing Loss or Severe Vertigo
If you experience an abrupt, sudden drop in your hearing, or if hearing changes are accompanied by severe vertigo (spinning dizziness) or vomiting, seek prompt evaluation by an ENT (ear, nose, and throat) specialist or emergency services. Do not wait for your next annual audiology appointment.
The Nature of the Hearing Loss
The hearing loss associated with this condition is typically sensorineural (meaning it involves the inner ear or the nerve) and bilateral (affecting both ears roughly equally) [3].
- Post-lingual Onset: Most people are born with normal hearing and begin to notice changes in early adulthood, with an average onset around age 26 in some studies, though childhood onset can occur [3][4].
- Progression: The loss is generally progressive. In one specific cohort study, average hearing thresholds declined by about 4 to 5.5 decibels per year [1][5]. However, this is a cohort-specific average, not an individual prediction. Onset, asymmetry, rate, and long-term severity vary substantially; in some cases, hearing remains stable, while others progress more rapidly [1].
- Complexity Beyond Volume: Many patients find that sounds are not just “quieter” but also less clear. You may have specific difficulty understanding speech in noisy rooms or locating where a sound is coming from [6]. This occurs because the variant can affect not only the cochlea (the hearing organ) but also the auditory nerve (retrocochlear dysfunction) and brainstem [7].
Managing with Hearing Aids and Accommodations
Hearing aids are the first line of treatment and are often very effective in the early to middle stages of the condition [8].
- Regular Testing: Because the loss is progressive, you should have a full audiological evaluation—including pure-tone audiometry and speech-perception testing—regularly [1].
- Verification: It is important that your audiologist performs “real-ear measurements” to verify that your hearing aids are providing the correct amount of amplification.
- Speech in Noise: Standard tests in quiet rooms may not fully capture your daily challenges. Asking for speech-in-noise testing can help your audiologist fine-tune your devices [6][7].
- Everyday Strategies: Broaden your communication strategies beyond just devices. Assistive listening technology (like FM systems), captioning, workplace or school accommodations, and psychosocial support can be immensely helpful.
When Hearing Aids Are Not Enough: Cochlear Implants
If hearing aids no longer provide enough clarity or volume to communicate, a cochlear implant (CI) may be considered. A CI bypasses the damaged parts of the inner ear to stimulate the auditory nerve directly [3].
- Implant Candidacy: Candidacy integrates aided speech testing, audiometry, ENT assessment, inner-ear/nerve imaging (like MRI/CT), and medical/anesthesia considerations. While Auditory Brainstem Response (ABR) is a useful test, it is only one component of evaluating candidacy [7].
- Variable Outcomes: While some observational series report positive speech-perception and detection outcomes, results are variable [9][10].
- The Neural Factor: It is important to have realistic expectations. Because mitochondrial disease can affect the auditory nerve itself (a “retrocochlear” issue), the benefit from an implant can sometimes be limited if the nerve cannot efficiently carry the signal to the brain [7][11].
- Long-Term Monitoring: In some cases, speech understanding may gradually decline several years after implantation [11]. This is thought to be due to the slow progression of the disease in the nerve pathways rather than a failure of the implant itself [11].
Early intervention and consistent follow-up are the best ways to preserve your ability to communicate and engage with the world around you.
Common questions in this guide
What type of hearing loss is linked to the m.3243A>G variant?
How quickly can hearing loss from m.3243A>G progress?
What hearing tests help monitor mitochondrial hearing loss?
Can hearing aids help with m.3243A>G-related hearing loss?
When should I ask about a cochlear implant?
Can a cochlear implant be less effective if the hearing nerve is affected?
Is sudden hearing loss with vertigo an emergency?
Get notified when new evidence is published on Mitochondrial DNA-related cardiomyopathy and hearing loss.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (11)
- 1
Long-Term Progression and Rapid Decline in Hearing Loss in Patients with a Point Mutation at Nucleotide 3243 of the Mitochondrial DNA.
Sakata A, Kashio A, Koyama H, et al.
Life (Basel, Switzerland) 2022; (12(4)) doi:10.3390/life12040543.
PMID: 35455034 - 2
Audiological and Vestibular Findings in Subjects with MELAS Syndrome.
Hougaard DD, Hestoy DH, Hojland AT, et al.
The journal of international advanced otology 2019; (15(2)):296-303 doi:10.5152/iao.2019.5913.
PMID: 31347509 - 3
Clinical characteristics and hearing impairment in carriers of the m.3243 A > G variant.
Uehara N, Fujita T, Uehara K, et al.
Journal of human genetics 2026; (71(3)):145-149 doi:10.1038/s10038-025-01412-3.
PMID: 41131326 - 4
Audio profiles in mitochondrial deafness m.1555A>G and m.3243A>G show distinct differences.
Iwanicka-Pronicka K, Pollak A, Skórka A, et al.
Medical science monitor : international medical journal of experimental and clinical research 2015; (21()):694-700 doi:10.12659/MSM.890965.
PMID: 25744662 - 5
Progression of Peripheral Vestibular Dysfunctions in Patients With a Mitochondrial A3243G Mutation.
Inoue A, Iwasaki S, Fujimoto C, et al.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2019; (40(3)):359-364 doi:10.1097/MAO.0000000000002091.
PMID: 30742597 - 6
Auditory and vestibular function in mitochondrial patients harbouring the m.3243A>G variant.
Stefanetti RJ, Newman J, Blain AP, et al.
Brain communications 2024; (6(6)):fcae361 doi:10.1093/braincomms/fcae361.
PMID: 39497799 - 7
Beyond the cochlea: exploring the multifaceted nature of hearing loss in primary mitochondrial diseases.
Koohi N, Holmes S, Male A, et al.
Brain communications 2024; (6(6)):fcae374 doi:10.1093/braincomms/fcae374.
PMID: 39584158 - 8
Audiological manifestations in mitochondrial encephalomyopathy lactic acidosis and stroke like episodes (MELAS) syndrome.
Vandana VP, Bindu PS, Sonam K, et al.
Clinical neurology and neurosurgery 2016; (148()):17-21.
PMID: 27359089 - 9
Cochlear Implantation Outcomes in Patients with Mitochondrial Hearing Loss: A Systematic Review and Narrative Synthesis.
Zia N, Nikookam Y, Muzaffar J, et al.
The journal of international advanced otology 2021; (17(1)):72-80 doi:10.5152/iao.2020.9226.
PMID: 33605225 - 10
The Outcome of Cochlear Implantation for Mitochondrial Disease Patients With Syndromic Hearing Loss.
Yamamoto N, Okuyama H, Hiraumi H, et al.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2015; (36(8)):e129-33 doi:10.1097/MAO.0000000000000817.
PMID: 26134938 - 11
Cochlear Implantation in Patients with Mitochondrial Gene Mutation: Decline in Speech Perception in Retrospective Long-Term Follow-Up Study.
Kanemoto K, Kashio A, Ogata E, et al.
Life (Basel, Switzerland) 2022; (12(4)) doi:10.3390/life12040482.
PMID: 35454973
This page is for education about hearing loss associated with m.3243A>G mitochondrial disease and does not replace medical advice. Seek urgent care for sudden hearing loss or severe vertigo, and discuss testing and treatment with an audiologist or ENT specialist.